Deucravacitinib (SOTYKTU™) is a first-in-class, highly selective, oral tyrosine kinase 2
(TYK2) inhibitor. It acts via an allosteric mechanism, binding to the catalytically inactive …

Janus kinase (JAK) inhibitors are disease-modifying agents with efficacy in treating a
spectrum of burdensome dermatologic conditions. The US Food and Drug Administration …

Background Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, inhibits
cytokine signaling in psoriasis pathogenesis. Objective The objective of this study was to …

Objective To assess the efficacy and safety of deucravacitinib, an oral, selective, allosteric
inhibitor of TYK2, in a phase II trial in adult patients with active systemic lupus erythematosus …

Background The use of monoclonal antibodies has changed the treatment of several
immune-mediated inflammatory diseases, including psoriasis. However, these large …

Introduction Psoriasis is a high-burden syndrome characterized by cutaneous and
extracutaneous manifestations that profoundly reduce patients' quality of life. The presence …

Introduction The management of moderate-to-severe forms of psoriasis is becoming a
frequent concern in geriatric age due to the higher risk to develop treatment adverse events …

Psoriasis is an immune-mediated disease, with the interleukin (IL)-23/IL-17 axis currently
considered its main pathogenic pathway. Tyrosine kinase 2 (TYK2) is responsible for …

Introduction Psoriasis management is challenging, especially in pediatric age for different
factors. The introduction of biologic drugs and oral small molecules (OSM) revolutionized the …

Psoriasis is a common, chronic, and inflammatory skin disease with a high burden on
individuals, health systems, and society worldwide. With the immunological pathologies and …